EBIO Eleven Biotherapeutics, Inc.

1.92
0  -1%
Previous Close 1.94
Open 1.99
Price To book 1.23
Market Cap 29.55M
Shares 15,393,000
Volume 185,959
Short Ratio 6.68
Av. Daily Volume 478,544

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2a trial to be initiated 2H 2017.
Proxinium
Squamous cell carcinoma of the head and neck - cancer
Phase 3 enrollment to be completed 2H 2017, with top-line data due 2018.
Vicinium
Non-muscle invasive bladder cancer (NMIBC)
Phase 3 topline data showed endpoints not met mid May 2015
Isunakinra (EBI-005)
Moderate to severe dry eye disease

Latest News

  1. ETFs with exposure to Eleven Biotherapeutics, Inc. : April 21, 2017
  2. Eleven Biotherapeutics Presents New Preclinical Data at AACR Supporting the Potential of the Company’s Locally- and Systematically-Administered Drug Candidates
  3. Eleven Biotherapeutics, Inc. :EBIO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017
  4. Eleven Biotherapeutics to Present New Preclinical Data at the American Association for Cancer Research Annual Meeting 2017
  5. Eleven Biotherapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Friday, March 24, 2017
  6. Eleven Biotherapeutics to Present at Oppenheimer's 27th Annual Healthcare Conference
  7. Eleven Biotherapeutics to Present at Upcoming Investor Conferences in March
  8. Eleven Biotherapeutics to Present at the 2017 BIO CEO & Investor Conference
  9. Eleven Biotherapeutics, Inc. :EBIO-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016
  10. Eleven Biotherapeutics Reports Third Quarter 2016 Financial Results
  11. Eleven Biotherapeutics to Report Third Quarter 2016 Financial Results on November 14, 2016
  12. ​Venture firm Third Rock raises $616M fund, names female partner
  13. 5 Companies That Destroyed Shareholders Last Week
  14. Eleven Biotherapeutics Acquires Viventia Bio
  15. Eleven Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  16. Eleven Biotherapeutics (EBIO) Stock Increases, Buys Viventia Bio
  17. Eleven Bio Finds Even More Pipeline Growth in M&A
  18. Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted Protein Therapeutics Oncology Company